Akebia Therapeutics (AKBA) Net Cash Flow (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Net Cash Flow of -$22.2 million for Q1 2026, down 136.08% year-over-year from $61.5 million in Q1 2025, and down 220.6% quarter-over-quarter from $18.4 million in Q4 2025.
Akebia Therapeutics (AKBA) Net Cash Flow (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Net Cash Flow for 14 consecutive years, with -$22.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 136.08% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at $49.3 million (down 31.0% YoY), while the FY2025 annual figure was $133.0 million, up 1382.48% from the prior year.
- Net Cash Flow eased to -$22.2 million in Q1 2026 per AKBA's latest filing, from $18.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $61.5 million in Q1 2025 and bottomed at -$54.7 million in Q4 2022.
- Historically, Net Cash Flow has averaged $735823.5 across 5 years, with a median of -$2.5 million in 2024.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 919.93% — and 2025, when it jumped 6527.27%.
- Akebia Therapeutics' Net Cash Flow stood at -$54.7 million in 2022, then surged by 93.42% to -$3.6 million in 2023, then jumped by 596.3% to $17.9 million in 2024, then increased by 3.06% to $18.4 million in 2025, then slumped by 220.6% to -$22.2 million in 2026.
- Business Quant data shows AKBA's Net Cash Flow at -$22.2 million in Q1 2026, $18.4 million in Q4 2025, and $29.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.60 Mn | 92.06 Mn | 38.70 Mn | -7.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 Mn |
| Jun 30, 2026 | -7.09 Mn |
| Mar 31, 2026 | -22.20 Mn |
| Mar 31, 2026 | -22.20 Mn |
| Dec 31, 2025 | 18.40 Mn |
| Dec 31, 2025 | 18.40 Mn |
| Sep 30, 2025 | 29.14 Mn |
| Sep 30, 2025 | 29.14 Mn |
| Jun 30, 2025 | 23.94 Mn |
| Jun 30, 2025 | 23.94 Mn |
| Mar 31, 2025 | 61.51 Mn |
| Mar 31, 2025 | 61.51 Mn |
| Dec 31, 2024 | 17.86 Mn |
| Dec 31, 2024 | 17.86 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Mar 31, 2024 | -957,000.00 |
| Mar 31, 2024 | -957,000.00 |